Business Standard / New Delhi September 19, 2008, 5:53 IST While the debate over the safety and efficacy of clinical trials in the country continues, another controversy has surfaced. The Indian edition of the Monthly Index of Medical Specialities (MIMS) has accused the Drugs Controller General of India (DCGI) of allowing the marketing of an oncology drug for treating infertility among women. MIMS argues that while marketing older drugs for new cures is a well-accepted practice, the drug has to undergo a fresh set of trials. This, MIMS says, did not happen